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Introduction: Rapid reductions in creatinine-based estimates of the 
glomerular filtration rate (GFR) have recently been reported second-
ary to crizotinib use. Whether these reflect drug-induced changes in 
the true GFR or the validity of creatinine as a measure of kidney 
function in the presence of crizotinib is unknown.
Methods: Two anaplastic lymphoma kinase–rearranged non–
small-cell lung cancer patients (one with pre-existing renal impair-
ment) were identified during periods of time on and off crizotinib. 
Creatinine- and iothalamate-based estimates of renal function were 
conducted in the presence and absence of crizotinib.
Results: Crizotinib is associated with both acute and chronic effects 
on kidney function. Chronic creatinine changes seem to reflect a true 
reduction in the GFR. In contrast, acute effects include a reduction 
in creatinine-based estimates of the GFR without a reduction in non-
creatinine–based measurements (consistent with, e.g., an acute effect 
of crizotinib on creatinine secretion), in addition to some reduction 
in the true GFR (with this latter effect seeming to be more prominent 
in the presence of pre-existing renal impairment).
Conclusion: If crizotinib-associated changes in creatinine-based 
kidney function suggest a change in dosing with either crizotinib 
or concomitant medications that are renally excreted, use of a non-
creatinine–based assessment of kidney function, such as iothalamate 
assessments, should be considered before making a final decision.
Key Words: Anaplastic lymphoma kinase, Crizotinib, Creatinine, 
Glomerular filtration rate.
(J Thorac Oncol. 2014;9: 1634–1637)
Crizotinib is a small-molecule, ATP-competitive, inhibi-tor of anaplastic lymphoma kinase (ALK), ROS1, and 
mesenchymal-epithelial transition (MET).1–3 Known side 
effects include gastrointestinal disturbance, elevated transami-
nases, rapid reduction in free testosterone levels in the major-
ity of men taking the drug, and asymptomatic bradycardia.4–6 
We recently reported apparent effects on kidney function as 
another side effect of crizotinib.7 Specifically, crizotinib rap-
idly produces a mean 23.9% drop in the creatinine-derived 
estimated glomerular filtration rate (eGFR) according to the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) calculation that could not be accounted for by dehy-
dration, by tumor lysis, or by the use of concomitant known 
nephrotoxic drugs or intravenous contrast.7–9 The majority of 
changes in eGFR occurs within 2 weeks of starting the drug 
and then plateaus. On cessation of dosing, eGFR was recover-
able to 84% of baseline values or above in all patients. Based 
on these data, we rejected the idea that crizotinib was directly 
nephrotoxic. Instead, within our initial report, we raised two 
possible mechanistic hypotheses: either crizotinib was some-
how interfering with a proportion of kidney function or it was 
altering the validity of creatinine as a measure of kidney func-
tion. This latter mechanism could occur, for example, through 
crizotinib competing with creatinine for secretion into the 
urine within the renal tubules, as has been described for some 
other drugs.10,11 Here, we present matched creatinine-based 
estimates of eGFR and direct measurements of the GFR using 
urinary creatinine clearance and/or iothalamate assessments in 
two patients both on and off crizotinib to inform this debate.12
PATIENTS AND METHODS
Two ALK-rearranged non–small-cell lung cancer patients 
(one with pre-existing renal impairment) were prospectively 
identified during periods of time on and off crizotinib. Vital 
signs and creatinine- and iothalamate-based estimates of renal 
function were conducted in the presence and absence of crizo-
tinib. The data were retrieved from patient electronic medical 
records in accordance with University of Colorado Institutional 
Review Board–approved protocol 09-018.
RESULTS
Case 1
A 53-year-old white male patient with stage IV adeno-
carcinoma of the lung developed chronic renal impairment 
secondary to initial chemotherapy exposure (six cycles of car-
boplatin and paclitaxel, followed by five cycles of cisplatin 
and pemetrexed and 12 cycles of maintenance pemetrexed). 
He initially had a complete response to the chemotherapy, but 
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18 months after the end of the chemotherapy his disease pro-
gressed. At this point, he had been identified as ALK positive 
and was started on crizotinib, at which point his pretreat-
ment creatinine was 2.05 mg/dl. He had a good radiographic 
response but was deemed intolerant of the drug due to recur-
rent elevations in serum creatinine associated with its use 
at all doses from 250 mg twice daily to 200 mg on alternate 
days, and crizotinib was discontinued.7 His disease remained 
largely in remission off crizotinib, with isolated areas of 
growth being controlled with stereotactic body radiation 
therapy. When further tumor growth manifested in his liver, 
due to our increased awareness of the potential reversibility 
and limited cumulative effect of crizotinib on renal function, 
it was considered safe to rechallenge with crizotinib 250 mg 
twice daily, in conjunction with increased vigilance of his 
renal function. Three days before recommencing crizotinib, 
his blood pressure and heart rate were 123/75 and 57 beats per 
minute (bpm), respectively. His serum creatinine was 2.09 mg/
dl, his eGFR calculated using the CKD-EPI prediction equa-
tion was 34 ml/min per 1.73 m2, and his creatinine clearance 
measured through a 24-hour urine collection was 47.38 ml/
min per 1.73 m2 (1426 mg creatinine/day in urine). After being 
on crizotinib for 15 days, his serum creatinine was 2.64 mg/
dl, his eGFR calculated using the CKD-EPI equation was 
26 ml/min per 1.73 m2, and his creatinine clearance measured 
through a 24-hour urine collection was 34.90 ml/min per 1.73 
m2 (1307 mg creatinine/day in urine). Urine microscopy was 
unremarkable and did not show any evidence of acute tubular 
necrosis (i.e., granular casts or renal tubular epithelial cells). 
Vital signs were available 30 days after being on crizotinib and 
showed a blood pressure and heart rate of 118/68 and 43 bpm, 
respectively. He had a complete metabolic and radiographic 
response on his first positron emission tomography/computed 
tomography scan performed after 6 weeks of therapy.
After approximately 5 months of therapy, his creati-
nine was recorded as 3.22 mg/dl, with a CKD-EPI eGFR of 
20 ml/min per 1.73 m2, and the decision was made to dis-
continue his crizotinib. His scans still showed no evidence 
of active disease, although his carcinoembryonic antigen 
(CEA) had increased from 18.6 at baseline to 49.9 ng/ml. His 
blood pressure and heart rate at this point were 115/68 and 
46 bpm, respectively. On the last day of dosing with crizo-
tinib, there had been some spontaneous improvement in his 
apparent renal function compared with the recordings 6 days 
beforehand. Specifically, his creatinine was 2.61 mg/dl, with 
a CKD-EPI eGFR of 26 ml/min per 1.73 m2. An iothala-
mate assessment obtained on the same day showed a GFR of 
37.3 ml/min per 1.73 m2. He discontinued his crizotinib, and 
23 days later his creatinine had fallen to 2.14 mg/dl, his CKD-
EPI eGFR had increased to 33 ml/min per 1.73 m2, his CEA 
had fallen to 24.9 ng/ml, and a repeat iothalamate assessment 
showed his GFR to have increased to 70.7 ml/min per 1.73 m2 
(Figs. 1 and 2A). Thirty days after crizotinib, his blood pres-
sure and heart rate were 108/65 and 64 bpm, respectively. The 
patient was not on any known nephrotoxic medication, and, 
apart from the cessation of his crizotinib, there were no other 
changes in medication use during this time.
Case 2
A 70-year-old white male with stage IV adenocarcinoma 
of the lung was initially treated with carboplatin, pemetrexed, 
and zoledronic acid for four cycles. Subsequent molecular test-
ing confirmed him to be ALK positive by fluorescence in situ 
hybridization analysis, and he commenced crizotinib at 250 mg 
twice daily. After 25 months of therapy, he developed oligopro-
gression in his sacrum and proximal left humerus and was treated 
with stereotactic body irradiation.13 After 4 months, he developed 
decreased vision in his right eye and was found to have a new 
retinal lesion and referred again for radiation therapy. A magnetic 
resonance imaging of his brain was unremarkable at the time.
At the start of his initial crizotinib therapy, his blood 
pressure and heart rate were 168/70 and 87 bpm, respectively, 
FIGURE 1.  Changes in serum creati-
nine and carcinoembryonic antigen 
(CEA) levels on commencement and 
cessation of crizotinib treatment 
in a patient with pre-existing renal 
impairment. Units of CEA (ng/ml) 
and creatinine (mg/dl) are shown 
on the y axis and dates of measure-
ments on the x axis. The green and 
blue horizontal lines represent the 
lower and upper limits of normal 
of each assay, respectively. Of note, 
CEA is known to be renally excreted, 
and the patient had a complete 
metabolic and radiographic response 
on positron emission tomography/
computed tomography scanning that 
occurred rapidly and persisted dur-
ing this period of time, despite the 
changes in CEA.
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his serum creatinine was 0.84 mg/dl, and his eGFR was 89 ml/
min per 1.73 m2 using the CKD-EPI equation. After nearly 2.5 
years on crizotinib, before holding his drug for retinal radia-
tion therapy, his serum creatinine had increased to 1.45 mg/
dl and his eGFR decreased to 47 ml/min per 1.73 m2 using 
the CKD-EPI equation. His blood pressure and heart rate 
on his last day of dosing were 149/66 and 67 bpm, respec-
tively. After being off drug for 9 days, his serum creatinine 
had fallen to 1.2 mg/dl and his eGFR had increased to 60 ml/
min per 1.73 m2 using the CKD-EPI equation. An iothalamate 
assessment performed within 24 hours of these blood results 
showed a direct measurement of his GFR to be 62.2 ml/min 
per 1.73 m2. Blood pressure and heart rate were not recorded 
while off the crizotinib. After 11 days, he then restarted on 
crizotinib at 250 mg twice daily, and all measurements were 
repeated after 26 days. At this point, his serum creatinine 
had increased to 1.53 mg/dl and his CKD-EPI eGFR fallen to 
44 ml/min per 1.73 m2 using the CKD-EPI equation. However, 
a second iothalamate assessment performed within 24 hours 
of these blood results while back on crizotinib showed his 
GFR to be higher than when off the crizotinib at 72.2 ml/min 
per 1.73 m2 (Figs. 1 and 2B). The patient did not have elevated 
CEA before, during, or after crizotinib exposure. Apart from 
the cessation and reintroduction of his crizotinib, there were 
no changes in any of his other medications during this time.
DISCUSSION
Our initial observation of the effect of crizotinib on 
serum creatinine and eGFR, the rapid onset and then plateau-
ing of the effect, and equally rapid reversibility raised sev-
eral etiological questions,7 specifically, whether these data 
reflected a true effect of crizotinib on kidney function or only 
on the accuracy of this particular method for assessing it, for 
example, through an effect on creatinine secretion. From case 
I, who had pre-existing renal damage, it is clear that crizotinib 
can affect both urinary creatinine clearance and iothalamate-
based direct measures of the GFR, in addition to the creatinine-
based eGFR. After 15 days of dosing, there was a 26% rise in 
creatinine, a 24% drop in eGFR as assessed by the CKD-EPI 
equation, and a 26% drop in the measured GFR as assessed 
by urinary creatinine clearance. Subsequently, on cessation of 
dosing with crizotinib, the patient manifested an 18% drop 
in serum creatinine (bringing the creatinine close to his pre-
crizotinib levels), a 27% increase in eGFR as assessed by the 
CKD-EPI equation, and an 89% increase in GFR as assessed 
by iothalamate (Figs. 1 and 2A). Iothalamate-based estimates 
of the GFR assume a “normal” distribution of intracellular and 
extracellular fluid. Beyond the background variability of the 
assessment (which has a reported coefficient of variation on 
repeated measurements of approximately 6–12%), only a true 
change in the GFR or significant changes in extravascular fluid 
accumulation (which did not occur) could explain the changes 
in the iothalamate readouts.12 In addition, CEA, a serum tumor 
marker that is known to be renally excreted, which had been 
rising coincidently with the rise in creatinine, despite a rapid 
and persistent metabolic and radiographic complete response, 
then manifested a 50% reduction after cessation of dosing 
with crizotinib, despite no other change in the patient’s anti-
cancer therapy or additional radiographic change in his cancer 
(Fig. 1).14 Given the changes in both iothalamate readings and 
CEA, a true effect of crizotinib on GFR has to be concluded, 
although an additional creatinine secretion effect cannot be 
ruled out. Certainly, the decrease in urinary creatinine (8%) 
with crizotinib in this one patient was below the mean reduc-
tion seen with other drugs that are known to interfere with 
creatinine secretion but was still within the range reported.15 
An acute event may have been associated with the immedi-
ate rise in the creatinine at the point when the decision was 
made to discontinue the patient’s dosing as these values were 
improving before discontinuing dosing. However, the overall 
trend had been of worsening renal function for several months 
previously, and as values fell further on discontinuation of 
crizotinib dosing, consistent with our prior recovery data set, 
A
B
FIGURE 2.  Changes in creatinine-based estimates of the glo-
merular filtration rate (GFR) using the Chronic Kidney Disease 
Epidemiology Collaboration equation (estimated GFR [eGFR]) 
and in non-creatinine–based measurements of the GFR using 
iothalamate assessments (measured GFR [mGFR]). A, In the 
patient with pre-existing renal impairment shown in Figure 
1, assessments were made while on crizotinib and then after 
holding crizotinib for 23 days, showing a minor improvement 
in the eGFR and a large improvement in the mGFR, consistent 
with some direct effect of crizotinib on true renal function, as 
supported by the changes in CEA independent of changes in 
radiographic tumor activity (see text). B, In a patient holding 
crizotinib for 9 days and then restarting the drug, although 
there was a reduction in the eGFR on restarting, the mGFR 
actually increased, suggesting that some acute effect of crizo-
tinib on creatinine secretion could also be occurring.
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the contribution of crizotinib exposure to the measured GFR 
readings remains unequivocal.7 How much the effect on the 
measured GFR reflects a direct effect of crizotinib on the kid-
ney, for example, through pharmacological inhibition of, as 
yet unknown, kinases involved in kidney function, versus an 
indirect effect, for example, secondary to renal hypoperfusion 
due to crizotinib-associated bradycardia remains uncertain. 
His blood pressure at the time of the bradycardia was neither 
markedly reduced nor elevated (115/68), but this does not pre-
clude an effect of the bradycardia on cardiac output and con-
sequently on renal perfusion per se as the local vasculature in 
the kidneys may not be reflective of the whole.
Case 2 also demonstrated results potentially consis-
tent with both slow-onset direct effects of crizotinib on the 
GFR and rapid-onset effects on creatinine secretion. Of note, 
unlike case 1, case 2 did not have pre-existing kidney dam-
age, and although there was again a suggestion of a crizo-
tinib-associated reduction in heart rate from baseline values, 
his heart rate never reached the bradycardic levels of case 1. 
Prolonged exposure to crizotinib was associated with a 73% 
increase in the patient’s creatinine and a 47% reduction in 
his eGFR, as assessed by the CKD-EPI equation, values too 
high to be explained by a pure creatinine secretion effect.10,11 
Subsequently, exploiting a break in crizotinib dosing for 
radiation therapy to obtain measures of kidney function taken 
before and after crizotinib exposure, cessation of crizotinib 
dosing was associated with a rapid 17% drop in serum cre-
atinine and a 28% increase in eGFR as assessed by the CKD-
EPI equation. Importantly, on recommencement of crizotinib 
dosing, although, as expected, there was a 28% rise in serum 
creatinine and a 27% decrease in eGFR as assessed by the 
CKD-EPI equation, there was no decrease in the measured 
GFR by iothalamate; instead there was actually a 16% increase 
in GFR from the initial iothalamate assessment. Assuming that 
some degree of intrapatient variability in iothalamate readings 
may be allowed for or that ongoing treatment of the under-
lying cancer may be marginally beneficial to renal function, 
here the suggestion is that crizotinib is not acutely affecting 
the true GFR but only the creatinine-based estimates of GFR, 
consistent with, for example, an effect on creatinine secretion.
Overall, these two cases illustrate what may be a range of 
different effects on kidney function associated with crizotinib 
use. Whereas in some situations crizotinib’s effects on kidney 
function may be restricted to interfering with assessments that 
are creatinine-based with minimal to no effect on the “true” GFR, 
in other situations, particularly after prolonged exposure, a clear 
reduction in the “true” GFR assessed through multiple differ-
ent means can occur. Consequently, consistent with our previous 
recommendations, if crizotinib-associated changes in creati-
nine-based kidney function are making practitioners consider 
a change in dosing with either crizotinib or concomitant medi-
cations that are renally excreted, use of a non-creatinine–based 
assessment of kidney function, such as iothalamate assessments, 
should be considered before making a final decision.
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